24/7 Market News – (NASDAQ:MITO) – Shares are currently at .39 cents and climbing with more than 1500 trades already in the pre-market.

(NASDAQ:MITO) – Shares are moving this morning up more than 45% on news of positive Phase 1 study results showing upper neuron improvement and safety.

Stealth BioTherapeutics Presents New SBT-272 Data Demonstrating Improvement in Upper Motor Neuron Function in ALS Disease Model at Keystone Neurodegeneration Symposium

24/7 Marketnews.com

SBT-272 improved neuronal health, superior to other approved and investigational agents

Phase 1 study to evaluate safety and tolerability of SBT-272 in healthy volunteers is underway Stealth BioTherapeutics Corp a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, announced today the presentation of new SBT-272 preclinical data demonstrating functional improvement in upper motor neurons with TDP-43 pathology, which plays a significant role in both amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). The data were presented at the Keystone Neurodegeneration Symposium in Keystone, CO held June 5-9,2022. A Phase 1 study to evaluate the safety and tolerability of SBT-272 in healthy volunteers is underway.


Signup today for free and be the first to get notified of breaking news.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.


Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist